Articles tagged "Induction therapy"

2015 American Transplant Congress
T-Cell Depletion Versus Interleukin-2 Antagonists in a Kidney Transplant Model of Sensitized Rhesus Macaques
C. Burghuber,^1,2 J. Kwun,¹ E. Page,¹ F. Leopardi,³ A. Gibby,¹ A. Farris,¹ N. Iwakoshi,¹ S. Knechtle.¹
¹Emory University, Atlanta, GA; ²Medical University Vienna, Vienna, Austria; ³Duke University, Durham, NC.
[Background] Sensitized patients comprise up to a third of the kidney waiting list. Preformed and newly formed alloantibodies post transplantation (TX) deteriorate graft survival, recall…
2015 American Transplant Congress
Impact of Induction Therapy on Outcomes in HIV + Renal Transplant Recipients
C. Kershaw,¹ C. Rogers,^2,4 M. Pavlakis,^1,2 H. Tang,² C. Alonso,^1,2 K. Khwaja,^2,3 A. Evenson,^2,3 K. Raven,^2,3 M. Wong.^1,2
¹Medicine, Beth Israel Deaconess Medical Center (BIDMC), Boston, MA; ²The Transplant Institute, BIDMC, Boston, MA; ³Surgery, BIDMC, Boston, MA; ⁴Pharmacy, BIDMC, Boston, MA.
Purpose: Kidney transplantation in HIV+ recipients has been complicated by higher than expected acute rejection rates (AR). Induction immunosuppression may or may not impact this…
2015 American Transplant Congress
The Relationship Between Age and Morbidity During the First Year Following Renal Transplantation in Patients Receiving Alemtuzumab Induction
S. LeCorchick, N. Wilson, C. Truscott, D. Shaffer, S. Karp, B. Concepcion, M. Stanley, I. Feurer, S. Bala.
Vanderbilt University Medical Center, Nashville.
BackgroundThe elderly (age ≥ 65) represent the largest growing patient population being listed for renal transplant. Immunosuppression in elderly patients presents a unique challenge, with…
2015 American Transplant Congress
Alemtuzumab Induction Is Associated With a Lower Risk of Early Rehospitalization After Kidney Transplant
G. Dube,¹ D. Tsapepas,² Y. Coppleson,³ L. Ratner,⁴ D. Cohen,¹ S. Mohan.¹
¹Medicine, Columbia University Medical Center, New York, NY; ²Pharmacy, New York-Presbyterian Hospital, New York, NY; ³Quality and Patient Safety, New York-Presbyterian Hospital, New York, NY; ⁴Surgery, Columbia University Medical Center, New York, NY.
Early rehospitalizations within the first 30 days (R-30D) are common after kidney transplant. R-30D are costly and associated with an increased risk of graft failure…
2015 American Transplant Congress
Induction Therapy Improves 15-Year Graft Survival in Kidney Transplant Recipients With Acute Rejection
R. Bajoka, M. Goggins, A. Patel.
Transplant Institute, Henry Ford Hospital, Detroit, MI.
Background: Graft(GS) and patient survival(PS) has been shown to be superior in patients without delayed graft function (DGF) or acute rejection(AR). Induction therapy(IT) is frequently…
2015 American Transplant Congress
Long Term Outcomes With Alemtuzumab Induction Therapy for Deceased and Living Renal Transplant Recipients. A Single Center Experience
P. Vaitla, U. Patel, A. Cruz, S. Guisti, A. Moiz, C.-S. Catherine, A. Cohen, G. Loss, H. Bohorquez, I. Carmody, T. Reichman, D. Bruce, S. Anders, J. Garces.
Ochsner Clinic Foundation, New Orleans, LA.
Background:Antibody induction therapy has been used for induction in up to 80% kidney transplant recipients according to United Network for Organ Sharing. It has been…
2015 American Transplant Congress
Deceased Donor HLA Antibody Incompatible Renal Transplantation Without Antibody Removal: High Incidence of Acute Rejection Reduced By T-Cell Depleting Induction Therapy
E. Jolly,¹ C. Taylor,² H. Morgan,² S. Peacock,² M. Clatworthy,¹ N. Torpey.¹
¹Division of Renal Medicine, Department of Medicine, University of Cambridge, Cambridge, United Kingdom; ²Tissue Typing Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
Aims: Screening for HLA-specific antibodies (Ab) is routine for patients on kidney transplant waiting lists, and HLA antigens to which a patient has detectable Ab…